|
WO2021050649A1
|
|
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
US2021100856A1
|
|
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
US2020338146A1
|
|
Variant aav capsids for intravitreal delivery
|
|
WO2020180951A1
|
|
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
WO2021050094A1
|
|
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
KR20190132626A
|
|
Compositions and Methods for Improved Gene Expression
|
|
CA3054687A1
|
|
Modified aav capsids and uses thereof
|
|
WO2018075798A1
|
|
Modified aav capsids and uses thereof
|
|
WO2017218981A2
|
|
Compositions and methods for reducing ocular neovascularization
|
|
AU2017286673A1
|
|
Treatment of AMD using AAV2 variant with aflibercept
|
|
EP3452065A1
|
|
Organotypic pig retina culture system
|
|
AU2017257169A1
|
|
Evasion of neutralizing antibodies by a recombinant adeno-associated virus
|
|
GB201608937D0
|
|
Mutant viral capsid libraries and related systems and methods
|
|
MX2017011041A
|
|
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones.
|
|
AU2015231439A1
|
|
Compositions and methods for enhanced gene expression in cone cells
|
